Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1439 - Phase II study of surgery after S-1 + oxaliplatin +bevacizumab therapy for unresectable rectal cancer by organ-preserved TME

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Surgical Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

Tatsuya Yoshida

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T. Yoshida1, T. Miura1, Y. Sakamoto1, H. Morohashi1, H. Fujita2, K. Sato1, K. Hakamada1

Author affiliations

  • 1 Gastroenterological Surgery, Hirosaki University Hospital, 036-8562 - Hirosaki/JP
  • 2 Radiology, Hirosaki University Hospital, 036-8562 - Hirosaki/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1439

Background

For unresectable locally advanced rectal cancer (ULARC), long-course preoperative neoadjuvant chemoradiotherapy (NACRT) was recommended by ESMO guideline. However, ULARC had the risk of not only local recurrence but also subsequent metastatic disease. In these circumstances, preoperative neoadjuvant intense chemotherapy without radiotherapy (NAC) are being investigated in multiple trials. The recent trials suggested equivalent local down staging and pCR rates of NAC using doublet therapy + bevacizumab as compared with standard NACRT. On the other hands, the addition of bevacizumab could be associated with anastomotic insufficiency or rectal perforation. Therefore, the strategy of the safe and sufficient introduction of preoperative doublet therapy + bevacizumab has been required for ULARC.

Trial design

Primary end point: T down-staging rate (The rate of pT0, pTis, pT1 and pT2) Inclusion criteria: 1. Clinical stage T3 or T4, any N without distant metastases. 2. Unresectable rectal cancer by organ-sparing TME which was judged by high resolution MRI. The features include CRM < =1mm, T4b, and lateral lymph node metastasis. Exclusion criteria: 1. Over 75 years old. 2. The patients had thromboembolism or significant abnormal electrocardiogram or cardiovascular disease. Protocol: S-1 is administered orally at 80mg/m2/day for 14 consecutive days followed by a 7 day rest. L-OHP is given intravenously on days 1, at a dose of 130mg/m2/day. Bevacizumab is given intravenously on days 1, at a dose of 7.5mg/kg/day. 21 days are assumed 1 course, and chemotherapy consisted of 4 courses. Surgery is carried out in 8 to 12 weeks after the end of chemotherapy. The type of surgery was defined by high resolution MRI after preoperative chemotherapy within 2 weeks before the date of surgery. Target sample: 32 patients Features of this trial: Paying attention to the safety and efficacy of bevacizumab compared with prior trials according to the following points; 1. long interval between surgery and the administration of bevacizumab. 2. The transverse loop colostomy is required before NAC in case of stenosis. 3. The diverting stoma are necessary after intestinal reconstruction.

Clinical trial identification

UMIN Clinical Trials Registry: UMIN000031626

Release date: 2018/03/08.

Legal entity responsible for the study

Aomori Colorectal Cancer Study (ACCS) group.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.